title: Serum microRNA-205 as a novel biomarker for cervical cancer patients.
abstract: OBJECTIVE
  Serum microRNAs (miRNAs) are a novel class of diagnostic and prognostic biomarkers for numerous cancers. However, the level and clinical relevance of circulating miR-205 transcripts in human serum of cervical cancer patients are unclear. The purpose of this study was to determine serum miR-205 levels in cervical cancer patients and explore its association with clinicopathological factors and prognosis.
  
  
  METHODS
  Serum miR-205 expression was investigated in 60 cervical cancer patients and 60 healthy normal controls by using real-time PCR. Correlations between miR-205 expression and the clinicopathological features and prognosis of cervical cancer patients were then evaluated. Receiver operating characteristic curves were used to evaluate the sensitivity and specificity of serum miR-205.
  
  
  RESULTS
  Serum miR-205 was significantly upregulated in cervical cancer patients compared with healthy donors (p < 0.01), and a high level of miR-205 expression was correlated with poor tumor differentiation (p = 0.009), lymph node metastasis (p = 0.015) and increased tumor stage (p = 0.001). The serum miR-205 level was capable of separating advanced stage from early stage metastatic cervical cancer from non-metastatic samples and poorly differentiated tumors from differentiated tumors with an area under the curve values of 0.74, 0.694 and 0.717, respectively. The expression of miR-205 was also higher in the cervical cancer tissues compared with the para-carcinoma tissues. In addition, Kaplan-Meier survival analysis showed that cervical cancer patients with high miR-205 expression tended to have shorter overall survival. In multivariate Cox regression analysis, miR-205 was identified as an independent prognostic marker.
  
  
  CONCLUSIONS
  Serum miR-205, which is upregulated in cervical cancer, represents a predictive biomarker for the prognosis of cervical cancer patients.
authors: Department of clinical laboratory, Jiangsu Province hospital on Integration of Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine, Jiangsu Branch of China Academy of Chinese Medical Science, Nanjing 210028, China.
authors: Quanhui
authors: Q
authors: Ma
authors: Department of obstetrics and gynecology, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China.
authors: Guiping
authors: G
authors: Wan
authors: Department of clinical laboratory, Jiangsu Province hospital on Integration of Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine, Jiangsu Branch of China Academy of Chinese Medical Science, Nanjing 210028, China.
authors: Shuxia
authors: S
authors: Wang
authors: Department of clinical laboratory, Jiangsu Province hospital on Integration of Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine, Jiangsu Branch of China Academy of Chinese Medical Science, Nanjing 210028, China.
authors: Wanwei
authors: W
authors: Yang
authors: Department of clinical laboratory, Jiangsu Province hospital on Integration of Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine, Jiangsu Branch of China Academy of Chinese Medical Science, Nanjing 210028, China.
authors: Jiaming
authors: J
authors: Zhang
authors: Department of clinical laboratory, Jiangsu Province hospital on Integration of Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine, Jiangsu Branch of China Academy of Chinese Medical Science, Nanjing 210028, China.
authors: Xiaoming
authors: X
authors: Yao
keywords: Biomarker; Cervical cancer; Diagnosis; Prognosis; Serum miR-205